EPO and stroke disorder: Specifically, GSK360A increased kidney EPO mRNA up to 80-fold (p<0.01) by 5 hours post-tMCAO stroke (i.e., an early induction of EPO mRNA by GSK360A) (Fig 9) that appears to contribute to the prolonged elevation of plasma EPO protein as shown in Fig 8.